Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $94.84 USD
Change Today +6.21 / 7.01%
Volume 464.4K
PBYI On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

puma biotechnology inc (PBYI) Snapshot

Open
$88.66
Previous Close
$88.63
Day High
$95.64
Day Low
$88.50
52 Week High
09/19/14 - $278.14
52 Week Low
08/26/15 - $79.29
Market Cap
3.1B
Average Volume 10 Days
456.2K
EPS TTM
$-6.43
Shares Outstanding
32.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PUMA BIOTECHNOLOGY INC (PBYI)

puma biotechnology inc (PBYI) Related Businessweek News

No Related Businessweek News Found

puma biotechnology inc (PBYI) Details

Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

134 Employees
Last Reported Date: 08/10/15
Founded in 2010

puma biotechnology inc (PBYI) Top Compensated Officers

Founder, Chairman of The Board, Chief Executi...
Total Annual Compensation: $910.0K
Senior Vice President of Finance & Administra...
Total Annual Compensation: $421.9K
Senior Vice President of Clinical Research an...
Total Annual Compensation: $475.8K
Compensation as of Fiscal Year 2014.

puma biotechnology inc (PBYI) Key Developments

Puma Biotechnology, Inc. Announces Board Changes

On August 11, 2015, the board of directors of Puma Biotechnology, Inc. increased the size of the Board from four to five directors and appointed Adrian Senderowicz, M.D., 51, to fill the resulting vacancy. Dr. Senderowicz will serve on the Board for a term expiring at the 2016 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board expects to appoint Dr. Senderowicz to serve on one or more committees of the Board at a subsequent date. Dr. Senderowicz served as the Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs from August 2014 to February 2015, and Clinical and Regulatory Strategy Officer from February 2015 to April 2015 of Ignyta, Inc.

Puma Biotechnology, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Expects to Publish Phase III ExteNET Trial Results

Puma Biotechnology, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of USD 64.9 million compared to USD 38.9 million a year ago. Net loss was USD 64.7 million compared to USD 38.8 million a year ago. Basic and diluted net loss per share was USD 2.01 compared to USD 1.29 a year ago. Non-GAAP adjusted net loss was USD 36.5 million compared to USD 31.6 million a year ago. Non-GAAP adjusted net loss per share was USD 1.13 compared to USD 1.05 a year ago. Net cash used in operating activities for the second quarter of 2015 was USD 34.6 million. For the six months, the company reported loss from operations of USD 117.1 million compared to USD 58.7 million a year ago. Net loss was USD 117.1 million compared to USD 58.6 million a year ago. Basic and diluted net loss per share was USD 3.68 compared to USD 1.96 a year ago. Non-GAAP adjusted net loss was USD 68.8 million compared to USD 46.3 million a year ago. Non-GAAP adjusted net loss per share was USD 2.16 compared to USD 1.55 a year ago. Net cash used in operating activities for the first half of 2015 was USD 84.6 million. For the second half of 2015, The company expects to publish Phase III ExteNET trial results in the extended adjuvant treatment of early stage HER2-positive breast cancer (anticipated in the third quarter of 2015); to perform additional presentations of the ExteNET Phase III trial (anticipated in the third and fourth quarters of 2015); to complete the company's ongoing Phase II FB-7 trial of PB272 as a neoadjuvant treatment for patients with HER2-positive breast cancer (anticipated in the third quarter of 2015); to report data from the company's Phase II trial of PB272 in HER2 non-amplified breast cancer that has a HER2 mutation (anticipated in the fourth quarter of 2015); report initial data from the Phase II trial of neratinib in extended adjuvant HER2 positive early stage breast cancer using loperamide prophylaxis (anticipated in the fourth quarter of 2015); complete the ongoing Phase II trial of PB272 in patients with HER2-positive metastatic breast cancer that has metastasized to the brain (anticipated in the second half of 2015); and (vii) expand additional cohorts in Phase II basket trial of PB272 in patients with solid tumors with activating HER2 mutations (anticipated in the second half of 2015).

Puma Biotechnology, Inc.(NYSE:PBYI) added to Russell 1000 Index

Puma Biotechnology, Inc. has been added to Russell 1000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBYI:US $94.84 USD +6.21

PBYI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBYI.
View Industry Companies
 

Industry Analysis

PBYI

Industry Average

Valuation PBYI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PUMA BIOTECHNOLOGY INC, please visit www.pumabiotechnology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.